SH-748 is under clinical development by Nanjing Sanhome Pharmaceutical and currently in Phase I for Relapsed Chronic Lymphocytic Leukemia (CLL). According to GlobalData, Phase I drugs for Relapsed Chronic Lymphocytic Leukemia (CLL) have a 73% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how SH-748’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
SH-748 overview
SH-748 is under development for the treatment of subcutaneous panniculitis-like T-cell lymphoma(SPTL), hematological tumors such as chronic lymphocytic leukemia (CLL) and relapsed and refractory chronic lymphocytic leukemia, small lymphocytic lymphoma. The drug candidate is administered through oral route as a tablet. It acts by targeting phosphatidylinositol 4,5 bisphosphate 3 kinase catalytic subunit delta (PIK3delta).
It was also under development for the treatment for the treatment of follicular lymphoma, marginal zone B-cell lymphoma, nodal marginal zone B-cell lymphoma and extranodal marginal zone B-cell lymphoma, relapsed or refractory Peripheral T Cell Lymphomas including peripheral T-cell lymphoma unspecified(PTCL-U), angioimmunoblastic T-cell lymphoma(AITL), ALK+/ALK-anaplastic large cell lymphoma(ALCL), and splenic marginal zone B-cell lymphoma.
Nanjing Sanhome Pharmaceutical overview
Nanjing Sanhome Pharmaceutical engaged in research, development, manufacturing and marketing of drugs including tablet, granule, lyophilized powder injection, capsule, powder injection ointments, large-capacity injection, small-capacity injection and others. The company is headquartered in Nanjing, Jiangsu, China.
For a complete picture of SH-748’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
